Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: Update on southwest oncology group study 9109

Urology

Volumn 79, Issue 3, 2012, Pages 633-637

  Berglund, Ryan K ^a   Tangen, Catherine M ^b   Powell, Isaac J ^c   Lowe, Bruce A ^d   Haas, Gabriel P ^e   Carroll, Peter R ^f   Canby Hagino, Edith D ^g   Devere White, Ralph ^h   Hemstreet III, George P ⁱ   Crawford, E David ^j   Thompson, Ian M ^k   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Statistical Center   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d Northwest Urologic Clinic   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BROOKE ARMY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^j UNIVERSITY OF COLORADO   (United States)

^k UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FOLLOW UP; GLEASON SCORE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; UNSPECIFIED SIDE EFFECT;

EID: 84857866070     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.11.019     Document Type: Article

References (14)

1. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial Lancet 360 9327 2002 103 106
2. D. Meltzer, B. Egleston, I. Abdalla Patterns of prostate cancer treatment by clinical stage and age Am J Public Health 91 1 2001 126 128 (Pubitemid 32049280)
3. R.K. Berglund, J.S. Jones, J.C. Ulchaker Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis Urology 67 6 2006 1253 1256 [Epub May 6, 2006] (Pubitemid 43818056)
4. S. Loeb, N.D. Smith, K.A. Roehl Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer Urology 69 6 2007 1170 1175 (Pubitemid 46891592)
5. S.J. Freedland, A.W. Partin, E.B. Humphreys Radical prostatectomy for clinical stage T3a disease Cancer 109 7 2007 1273 1278 (Pubitemid 46466553)
6. J.F. Ward, J.M. Slezak, M.L. Blute Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome BJU Int 95 6 2005 751 756 (Pubitemid 40547200)
7. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer: 2008 Fort Washington, Pa. Prostate Cancer. V.1.2009 2008
8. O.R. El Hayek, W. Alfer Jr, E. Reggio Percutaneous prostate cryoablation as treatment for high-risk prostate cancer Clinics (Sao Paulo) 62 2 2007 109 112
9. Y. Yoshioka, K. Konishi, R.J. Oh High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer Radiother Oncol 80 1 2006 62 68 [Epub July 25, 2006] (Pubitemid 44226435)
10. I.J. Powell, C.M. Tangen, G.J. Miller Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109 J Urol 168 5 2002 2016 2019
11. D.V. Makarov, E.B. Humphreys, L.A. Mangold Pathologic outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6-4.0 versus 4.1-6.0 ng/mL J Urol 176 2 2006 554 558 (Pubitemid 43927930)
12. P.J. Saylor, M.R. Smith Metabolic complications of androgen deprivation therapy for prostate cancer J Urol 181 5 2009 1998 2006 [discussion 2007-2008]. [epub March 14, 2009]
13. I.M. Thompson, C.M. Tangen, J. Paradelo Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 3 2009 956 962 [epub January 23, 2009]
14. M. Bolla, H. van Poppel, L. Collette Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22 911) Lancet 366 9485 2005 572 578 (Pubitemid 41140332)